間中 勝則 まなか かつのり 先生

来歴等

略歴

2004年 東京大学医学部 卒業
2011年 東京大学大学院内科学専攻 終了 医学博士取得
2013年 東京大学 健康保健推進センター 助教
2014年 東京大学医学部附属病院 腎臓・内分泌内科 助教

論文

• 1. Aldosterone-Producing Adenomas of Increased Size Are Associated With Higher Steroidogenic Activity.

  Nakai K, Manaka K, Sato J, Takeuchi M, Yamazaki Y, Sasano H, Tsurutani Y, Saito J, Nishikawa T, Iiri T, Nangaku M, Makita N. J Clin Endocrinol Metab. 2022 Nov 23;107(11):3045-3054.

• 2. Successful prednisolone or calcimimetic treatment of acquired hypocalciuric hypercalcemia caused by biased allosteric CaSR autoantibodies.

  Makita N, Sato J, Manaka K, Akahane K, Ito T, Yamazaki H, Mizoguchi A, Hikima Y, Horikoshi H, Nangaku M, Iiri T. JCI Insight. 2022 Oct 24;7(20):e156742.

• 3. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance.

  Hamada T, Morita A, Suga H, Boki H, Fujimura T, Hirai Y, Shimauchi T, Tateishi C, Kiyohara E, Muto I, Nakajima H, Abe R, Fujii K, Nishigori C, Nakano E, Yonekura K, Funakoshi T, Amano M, Miyagaki T, Makita N, Manaka K, Shimoyama Y, Sugaya M. J Dermatol. 2022 Feb;49(2):253-262.

• 4. Clinical Characteristics and Incidences of Benign and Malignant Insulinoma Using a National Inpatient Database in Japan.

  Kurakawa KI, Okada A, Manaka K, Konishi T, Jo T, Ono S, Uda K, Michihata N, Matsui H, Fushimi K, Yamaguchi S, Yamauchi T, Nangaku M, Yasunaga H, Kadowaki T. J Clin Endocrinol Metab. 2021 Nov 19;106(12):3477-3486.

• 5. Neuroendocrine manifestations of Erdheim-Chester disease.

  Manaka K, Sato J, Makita N. Handb Clin Neurol. 2021;181:137-147.

• 6. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.

  Manaka K, Sato J, Takeuchi M, Watanabe K, Kage H, Kawai T, Sato Y, Miyagawa T, Yamada D, Kume H, Sato S, Nagase T, Iiri T, Nangaku M, Makita N. Sci Rep. 2021 Jun 2;11(1):11617.

• 7. Position paper from the Japan Thyroid Association task force on the management of low-risk papillary thyroid microcarcinoma (T1aN0M0) in adults.

  Horiguchi K, Yoshida Y, Iwaku K, Emoto N, Kasahara T, Sato J, Shimura H, Shindo H, Suzuki S, Nagano H, Furuya F, Makita N, Matsumoto F, Manaka K, Mitsutake N, Miyakawa M, Yokoya S, Sugitani I. Endocr J. 2021 Jul 28;68(7):763-780.

• 8. Comparison between the clinical characteristics of patients with adrenal incidentalomas and those with hypertension-associated adrenal tumors in a single center in Japan.

  Aoe M, Okada A, Usui T, Manaka K, Nangaku M, Makita N. Endocr J. 2020 Jun 29;67(6):645-654.

• 9. V2 vasopressin receptor mutations.

  Makita N, Manaka K, Sato J, Iiri T. Vitam Horm. 2020;113:79-99.

• 10. Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience.

  Manaka K, Sato J, Kinoshita Y, Ito N, Fujita M, Iiri T, Nangaku M, Makita N. Endocr J. 2019 Aug 29;66(8):683-689.

• 11. Bexarotene-induced hypothyroidism: Characteristics and therapeutic strategies.

  Makita N, Manaka K, Sato J, Mitani K, Nangaku M, Iiri T. Clin Endocrinol (Oxf). 2019 Jul;91(1):195-200.